Denecimig
An investigational treatment for Hemophilia A.
The same compound appears under different names depending on the context. Here is how to identify Denecimig wherever you encounter it, plus the key facts at a glance.
- Generic name
- Denecimig
- Development codes
- Mim8, NNC0365-3769
- Drug class
- Factor VIIIa mimetic bispecific antibody
- Manufacturer
- Novo Nordisk
- How it's taken
- Injected under the skin from a single-use prefilled pen, once a month, once every 2 weeks or once a week, according to Novo's European filing.
Novo Nordisk's once-monthly, every-2-week or once-weekly under-the-skin prophylaxis for hemophilia A with or without inhibitors, under FDA review since September 2025 and recommended for EU approval as Frehemgo on September 17, 2026. It works the same way as Hemlibra, standing in for factor VIII, and is given from a single-use prefilled pen.
Where Denecimig fits
If approved, denecimig would be the second factor VIIIa mimetic after Hemlibra and the first non-factor hemophilia A drug designed for once-monthly dosing from the start. Hemlibra already offers an every-4-week schedule. The 2 drugs have not been compared head to head; the switch data from FRONTIER5 are the evidence a hematologist would use for people moving from one to the other.
How Denecimig works
Factor VIII's job is to hold 2 other clotting proteins, factor IXa and factor X, together long enough for a clot to form. Denecimig is an antibody with 2 arms that grabs one of those proteins with each arm and does that bridging job itself. Because it is not factor VIII, the inhibitor antibodies some people develop against factor VIII replacement do not block it. This is the same approach as emicizumab (Hemlibra); Novo designed denecimig for less frequent dosing, as seldom as once a month.
Mechanism: Bispecific antibody that bridges factor IXa and factor X, mimicking activated factor VIII
Side effects and safety
In the Phase 3 FRONTIER2 trial, injection site reactions were reported by 10% of participants and occurred with 2.6% of injections. No blood clots and no clinical evidence of neutralizing antibodies against denecimig were reported. A US label does not yet exist, so the full warnings are not known; Hemlibra, which works the same way, carries a boxed warning about blood clots and thrombotic microangiopathy when combined with high doses of the bypassing agent aPCC.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Denecimig
Injected under the skin from a single-use prefilled pen, once a month, once every 2 weeks or once a week, according to Novo's European filing. Final US dosing will be set by the FDA label.
Clinical trial results
FRONTIER2 (NCT05053139) included 254 people aged 12 and older in its main analysis with hemophilia A, 12% of them with inhibitors, and compared 26 weeks of monthly or weekly denecimig with each person's prior treatment. Monthly denecimig cut treated bleeds by about 99% versus on-demand treatment and about 43% versus prior factor prophylaxis; weekly denecimig cut them by about 96% and 54%. Between 64% and 95% of people on denecimig had no treated bleeds, depending on the arm. Results were published in the New England Journal of Medicine on April 30, 2026. FRONTIER3 tested the drug in children under 12, FRONTIER4 is the long-term extension, and FRONTIER5 switched people directly from emicizumab with no new safety signals.
Development history
Novo Nordisk submitted a biologics license application to the FDA in September 2025. A US decision was expected in the third quarter of 2026, according to the company's August 4, 2026 half-year report, and none had been announced when that quarter ended on September 30th. On September 17, 2026 the European Medicines Agency's CHMP recommended approval under the brand name Frehemgo for adults and children with hemophilia A, with or without inhibitors, and Novo said it plans to launch in the first European countries in the fourth quarter of 2026.
Explore Hemophilia A trials
Other Hemophilia A treatments
Common questions about Denecimig
▸What is Denecimig?
Novo Nordisk's once-monthly, every-2-week or once-weekly under-the-skin prophylaxis for hemophilia A with or without inhibitors, under FDA review since September 2025 and recommended for EU approval as Frehemgo on September 17, 2026. It works the same way as Hemlibra, standing in for factor VIII, and is given from a single-use prefilled pen.
▸How does Denecimig work?
Factor VIII's job is to hold 2 other clotting proteins, factor IXa and factor X, together long enough for a clot to form. Denecimig is an antibody with 2 arms that grabs one of those proteins with each arm and does that bridging job itself. Because it is not factor VIII, the inhibitor antibodies some people develop against factor VIII replacement do not block it. This is the same approach as emicizumab (Hemlibra); Novo designed denecimig for less frequent dosing, as seldom as once a month.
▸What are the side effects of Denecimig?
In the Phase 3 FRONTIER2 trial, injection site reactions were reported by 10% of participants and occurred with 2.6% of injections. No blood clots and no clinical evidence of neutralizing antibodies against denecimig were reported. A US label does not yet exist, so the full warnings are not known; Hemlibra, which works the same way, carries a boxed warning about blood clots and thrombotic microangiopathy when combined with high doses of the bypassing agent aPCC.
▸How is Denecimig taken?
Injected under the skin from a single-use prefilled pen, once a month, once every 2 weeks or once a week, according to Novo's European filing. Final US dosing will be set by the FDA label.
▸Is Denecimig FDA approved?
Not yet. Denecimig is under FDA review for Hemophilia A; Novo Nordisk has filed an application and a decision is expected Q3 2026. The FDA calendar page tracks the outcome.
▸When will the FDA decide on denecimig?
A US decision was expected in the third quarter of 2026, according to Novo Nordisk's August 2026 half-year report, and none had been announced when the quarter ended on September 30th. The FDA calendar page for denecimig is updated when the decision is announced.
▸How is denecimig different from Hemlibra?
Both are factor VIIIa mimetics that bridge factor IXa and factor X. Denecimig was built to be given once a month, every 2 weeks or weekly from a prefilled pen; Hemlibra is dosed by weight weekly, every 2 weeks or every 4 weeks after a loading period. They have not been compared in a trial. FRONTIER5 switched people directly from emicizumab to denecimig and reported no new safety signals.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Novo Nordisk via PR Newswire · 2026-04-29. Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM. https://www.prnewswire.com/news-releases/denecimig-mim8-significantly-reduced-annualized-bleeding-rate-in-people-with-hemophilia-a-regardless-of-inhibitor-status-in-phase-3-data-published-in-nejm-302757974.html
- New England Journal of Medicine · 2026-04-30. Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors. https://www.nejm.org/doi/10.1056/NEJMoa2517384
- Novo Nordisk via GlobeNewswire · 2026-09-17. Novo: CHMP recommends EU approval of FREHEMGO (denecimig) for the treatment of haemophilia A. https://www.globenewswire.com/news-release/2026/09/17/3364155/0/en/novo-chmp-recommends-eu-approval-of-frehemgo-denecimig-the-first-factor-viiia-mimetic-offering-monthly-once-every-two-weeks-and-weekly-dosing-in-a-pre-filled-pen-for-the-treatment-.html
- Novo Nordisk · 2026-08-04. Financial report for the period 1 January 2026 to 30 June 2026. https://ml-eu.globenewswire.com/Resource/Download/59861be7-056f-420d-985b-a7e976f8426d